Advisor Group Holdings, Inc. Chemomab Therapeutics Ltd. Transaction History

Advisor Group Holdings, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.59 - $1.29 $590 - $1,290	1,000 New	1,000 $0
Q4 2023 Feb 12, 2024	SELL	$0.45 - $0.9 $535 - $1,071	-1,190 Reduced 67.04%	585 $0
Q3 2023 Nov 13, 2023	SELL	$0.9 - $1.42 $855 - $1,349	-950 Reduced 34.86%	1,775 $1,000
Q1 2023 May 12, 2023	SELL	$1.44 - $2.94 $5,254 - $10,728	-3,649 Reduced 57.25%	2,725 $4,000
Q4 2022 Feb 10, 2023	SELL	$1.9 - $3.2 $1,164 - $1,961	-613 Reduced 8.77%	6,374 $20,000
Q3 2022 Nov 14, 2022	SELL	$2.33 - $4.0 $1,726 - $2,964	-741 Reduced 9.59%	6,987 $18,000
Q2 2022 Aug 10, 2022	BUY	$2.58 - $4.88 $1,506 - $2,849	584 Added 8.17%	7,728 $29,000
Q1 2022 May 04, 2022	SELL	$3.53 - $7.2 $168,299 - $343,274	-47,677 Reduced 86.97%	7,144 $34,000
Q3 2021 Nov 05, 2021	BUY	$11.08 - $19.17 $607,416 - $1.05 Million	54,821 New	54,821 $608,000

4.55M

Ticker CMMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,431,700
Market Cap $18.9M
Description
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.